NASDAQ: PODDInsulet Corp Stock
$143.52-4.17 (-2.82%)
Updated Jun 17, 2026
PODD Price
$143.52
Fair Value Price
$29.53
Market Cap
$9.94B
52 Week Low
$140.63
52 Week High
$354.88
P/E
33.38x
P/B
7.63x
P/S
5.06x
PEG
1x
Dividend Yield
N/A
Revenue
$2.90B
Earnings
$302.80M
Gross Margin
71%
Operating Margin
16.17%
Profit Margin
10.4%
Debt to Equity
1.29
Operating Cash Flow
$619M
Beta
1.05
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PODD Overview
Insulet Corporation specializes in the creation, production, and distribution of advanced insulin management systems for individuals living with insulin-dependent diabetes. At the core of their offerings is the Omnipod System, an innovative solution featuring a unique, self-adhesive, and disposable Omnipod device. This tubeless unit can be directly applied to the body for a duration of up to three days, and it operates in conjunction with a wireless handheld personal diabetes manager. The company's products reach customers predominantly through independent distributors and pharmaceutical channels, though direct sales also occur. Geographically, Insulet serves markets spanning the United States, Canada, Europe, the Middle East, and Australia. Established in 2000, the corporation's headquarters are located in Acton, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PODD's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
PODD
Ranked#7 of 93
Ranked#7 of 93
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.54 | A | |
| $37.14 | A | |
| $25.83 | A |
Be the first to know about important PODD news, forecast changes, insider trades & much more!
PODD News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PODD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PODD ($143.52) is overvalued by 386.03% relative to our estimate of its Fair Value price of $29.53 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PODD ($143.52) is not significantly undervalued (386.03%) relative to our estimate of its Fair Value price of $29.53 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PODD ($143.52) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PODD due diligence checks available for Premium users.
Valuation
PODD fair value
Fair Value of PODD stock based on Discounted Cash Flow (DCF)
Price
$143.52
Fair Value
$29.53
Overvalued by
386.03%
PODD ($143.52) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PODD ($143.52) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PODD ($143.52) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PODD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
33.38x
Industry
20.33x
Market
12.4x
PODD is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PODD is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
PODD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.63x
Industry
2.92x
PODD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PODD price to earnings growth (PEG)
For valuing profitable companies with growth potential
PODD is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
PODD's financial health
Profit margin
Revenue
$761.7M
Net Income
$91.1M
Profit Margin
12%
PODD's Earnings (EBIT) of $469.10M... subscribe to Premium to read more.
Interest Coverage Financials
PODD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.0B
Liabilities
$1.7B
Debt to equity
1.29
PODD's short-term assets ($1.71B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PODD's short-term assets ($1.71B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PODD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PODD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$113.8M
Investing
-$27.7M
Financing
-$319.9M
PODD's operating cash flow ($619.30M)... subscribe to Premium to read more.
Debt Coverage Financials
PODD vs Medical Device Stocks
Insulet Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.